Search Results
Your search for ,ARE matches 21425 pages
Showing 6001 - 6050Expert Point of View: Marcus Noel, MD, and Susan Tsai, MD, MHS
Marcus Noel, MD, Associate Professor of Medicine at Lombardi Comprehensive Cancer Center and MedStar Georgetown University Hospital, Washington, DC, included SWOG S1505 in the presentation of the Gastrointestinal Cancer Highlights during the ASCO20 Virtual Scientific Program. Susan Tsai, MD, MHS, a ...
Novel CK2 Inhibitor Silmitasertib Shows Promise in Cholangiocarcinoma
A novel inhibitor of casein kinase 2 (CK2) has shown preliminary evidence of efficacy in patients with locally advanced or metastatic cholangiocarcinoma, according to a phase I/IIb study presented at the 2021 Gastrointestinal Cancers Symposium.1 Silmitasertib (CX-4945) is an oral small-molecule...
In Cholangiocarcinoma, Does Chemotherapy Response Vary According to FGFR2 Status?
With inhibitors of fibroblast growth factor receptor 2 (FGFR2) fusion and other genetic alterations now in clinical trials for cholangiocarcinoma, there is interest in better understanding what FGFR2 genetic alterations mean for patients. In particular, little is known about the effects of FGFR2...
Expert Point of View: Rachna T. Shroff, MD, and Gentry King, MD
Invited study discussant Rachna T. Shroff, MD, Associate Professor of Medicine, University of Arizona, and Chief of GI Medical Oncology at the University of Arizona Cancer Center, said the study presented by Dr. Javle showed the FGFR2 inhibitor infigratinib to be active in FGFR2 fusion–positive...
FGFR2 Inhibitor Infigratinib Active in Chemotherapy-Refractory Cholangiocarcinoma
The novel targeted agent infigratinib (BGJ398) showed clinically meaningful activity against chemotherapy-refractory cholangiocarcinoma in patients with fibroblast growth factor receptor (FGFR2) fusions and rearrangements. The confirmed overall response rate was 23% (34% confirmed/unconfirmed), the ...
Expert Point of View: Rachna T. Shroff, MD
Invited discussant of the ClarIDHy trial, Rachna T. Shroff, MD, Associate Professor of Medicine, University of Arizona, and Chief of GI Medical Oncology at the University of Arizona Cancer Center, said positive findings for ivosidenib support the notion that “biliary cancer is a perfect example of...
ClarIDHy Trial: IDH1 Inhibitor Ivosidenib Improves Survival in Cholangiocarcinoma
Ivosidenib, an inhibitor of isocitrate dehydrogenase 1 (IDH1), improved overall survival by almost 3 months in previously treated patients with advanced IDH1-mutated cholangiocarcinoma, compared with placebo, researchers of the global phase III ClarIDHy trial reported at the 2021 Gastrointestinal...
ASCO Names Advance of the Year: Molecular Profiling Drives Progress in Gastrointestinal Cancers
Molecular profiling allows clinicians to identify the molecular and genetic signatures that help to deliver treatments that are highly specific to a tumor. This tool has made possible a number of advances in the past year that are improving care for patients with gastrointestinal cancers. In...
IMbrave150: A New Standard of Care to Treat Hepatocellular Cancers?
In 2007, sorafenib became the first approved systemic therapy for hepatocellular cancers and the first agent to improve overall survival in these patients.1 In a similar multikinase inhibitor strategy, lenvatinib was found to be noninferior to sorafenib in overall survival in the same patient...
Solving the Mystery of Why Colorectal Cancer Is on the Rise in Young Adults
Excluding skin cancer, colorectal cancer is the third most prevalent and lethal cancer among both men and women in the United States.1 Although the risk of developing colorectal cancer increases with age—more than 90% of cases occur in people aged 50 or older2—recent research shows that the...
Molecular Testing in Metastatic Colorectal Cancer: Understanding How, When, and What to Profile
“In line with the emergence of targeted therapies, molecular biomarker testing in metastatic colorectal cancer has evolved over the past decade,” noted Jeanne Tie, MD, MBChB, FRACP, who acknowledged there is confusion about the best ways to use molecular testing in the clinic. Dr. Tie, who is...
Expert Point of View: Christopher Leigh Hallemeier, MD
The invited discussant for the RAPIDO and PRODIGE 23 trials, Christopher Leigh Hallemeier, MD, Associate Professor of Radiation Oncology at the Mayo Clinic, Rochester, noted the standard approach to locally advanced rectal cancer has been, for the past 2 decades, a long course of chemoradiotherapy ...
Some Patients With Lung Cancer Report Feeling Uninformed About Their Disease, Uninvolved With Their Treatment
More than 1 in 10 patients with lung cancer do not know what type of tumor they have, according to data from a 17-country study carried out by the Global Lung Cancer Coalition (GLCC) presented by Beattie et al at the European Lung Cancer Virtual Congress 2021 (Abstract 209P_PR). Nearly one in five...
Two Studies Validate Neoadjuvant Chemotherapy With Short-Course Radiotherapy or Long-Term Chemoradiotherapy in Locally Advanced Rectal Cancer
In the treatment of resectable, locally advanced rectal cancer, researchers are trying to identify the most effective chemotherapy regimens, the best radiotherapy approaches, and the optimal sequence of these modalities. Two phase III trials presented during the ASCO20 Virtual Scientific Program...
Expert Point of View: Autumn McRee, MD
DESTINY-CRC01 study discussant, Michael S. Lee, MD, Assistant Professor of Medicine, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, called the findings “most promising” for the subsequent anti-HER2 treatment of HER2-positive metastatic colorectal cancer. The...
Fam-Trastuzumab Deruxtecan-nxki Shows Benefit in Refractory Colorectal Cancer
Having recently gained approval in metastatic breast cancer, fam-trastuzumab deruxtecan-nxki (T-DXd) is now proving its worth in metastatic colorectal cancer, according to results of the phase II DESTINY-CRC01 study in patients with HER2-positive disease.1 T-DXd is an antibody-drug conjugate...
Expert Point of View: Michael Overman, MD
At the 2021 Gastrointestinal Cancers Symposium, the KEYNOTE-177 investigators updated their previously reported findings by showing further data relating to subsequent lines of therapy after disease progression. Their conclusion was that patients who received pembrolizumab initially still achieved...
KEYNOTE-177: New Analysis Confirms Benefit of Pembrolizumab vs Chemotherapy in Microsatellite Instability–High Advanced Colorectal Cancer
In an updated analysis of the pivotal phase III KEYNOTE-177 trial of pembrolizu-mab for microsatellite instability–high (MSI-H) metastatic colorectal cancer, the benefit of first-line pembrolizumab continued beyond disease progression on the subsequent line of treatment, despite a high crossover to ...
Treating Colorectal Cancer in the Time of COVID-19
The treatment of colorectal cancer has always been something of an art—but never more so than during the COVID-19 pandemic. In the spring of 2020, The ASCO Post asked three experts in this malignancy to share their concerns and their approaches to achieving good patient outcomes while minimizing...
Gastrointestinal Oncology Highlights 2020–2021 Almanac
Cancers of the digestive tract account for 338,090 new cases and 169,280 deaths annually in the United States. Although the overall mortality from these cancers is decreasing, this has been countered by an increase in the incidence of colorectal cancer in young adults. The rising incidence and poor ...
Adagrasib for Patients With Advanced KRAS G12C–Mutated NSCLC
Treatment with the KRAS G12C inhibitor adagrasib showed clinical activity in patients with advanced non–small cell lung cancer (NSCLC) harboring a KRAS G12C mutation, confirming its role as a therapeutic target. Results from the KRYSTAL-1 trial were reported at the European Lung Cancer Virtual...
Definitive Ablative Radiation Therapy in Inoperable Locally Advanced Pancreatic Cancer
In a single-institution study reported in JAMA Oncology, Reyngold et al found that definitive hypofractionated ablative radiation therapy following induction chemotherapy was associated with prolonged locoregional control and favorable survival in patients with inoperable locally advanced...
Younger vs Older Women With Breast Cancer: Understanding the Differences
Younger women with breast cancer differ from their older counterparts in ways that should be appreciated by their clinicians, according to Ann H. Partridge, MD, MPH, FASCO, Vice Chair of Medical Oncology at Dana-Farber Cancer Institute and Professor of Medicine at Harvard Medical School. At PER’s...
UC Davis Comprehensive Cancer Center Elected as NCCN Member Institution
The National Comprehensive Cancer Network® (NCCN®) announced that its board of directors has voted to elect the University of California (UC) Davis Comprehensive Cancer Center as its newest member institution. UC Davis joins 30 other leading academic cancer centers from across the United States...
I Want to Live Long and I Want to Live Well
I’m a person who doesn’t like uncertainty. I’m also a worrier. So, when my hand kept going to the same spot on the upper part of my left breast near my chest wall, I couldn’t shake the feeling that something wasn’t quite right, which persisted even after a routine mammography failed to find any...
ASTRO Recommendation on COVID-19 Vaccination for Patients Receiving Radiation Therapy
The American Society for Radiation Oncology (ASTRO) has compiled a selection of resources for radiation oncology professionals. The resources were developed by clinical teams and based on the best available information at the time they were posted. Physicians and their patients must make the...
Memorial Sloan Kettering Establishes Tow Center for Developmental Oncology
Memorial Sloan Kettering Cancer Center (MSK) recently announced the establishment of The Tow Center for Developmental Oncology (TCDO). The new institution will bring together the unique expertise of researchers and physicians from across MSK and empower them to pursue translational research...
Ravi Bellamkonda, PhD, Named Provost of Emory University
Emory University President Gregory L. Fenves, PhD, recently announced the appointment of biomedical scientist Ravi Bellamkonda, PhD, as the university’s next Provost and Executive Vice President for Academic Affairs, effective July 1, 2021. Dr. Bellamkonda returns to Emory after serving as Dean of...
Hans Clevers, MD, PhD, FAACR, Recognized With 2021 Pezcoller Foundation–AACR International Award
The Pezcoller Foundation–American Association for Cancer Research (AACR) International Award for Extraordinary Achievement in Cancer Research will be presented to Hans Clevers, MD, PhD, FAACR, at the virtual AACR Annual Meeting 2021, to be held April 10–15 and May 17–21. Dr. Clevers, who is...
Eleven Oncology Practices Receive Quality Certification From the Association for Clinical Oncology
The Association for Clinical Oncology congratulates the 11 practices that prioritized the quality of care they provide by achieving the Quality Oncology Practice Initiative (QOPI®) Certification in the second half of 2020. These practices have shown that they are committed to providing the...
Breast Cancer Susceptibility Genes: Putting the Pieces Together
With the widespread use of multigene panels for germline genetic testing, understanding the cancer risks associated with pathogenic or likely pathogenic variants (ie, mutations) has become increasingly necessary. To identify which genes are breast cancer susceptibility genes, population studies...
Health-Care Policy Expert Sybil R. Green, JD, RPh, MHA, Brings Wealth of Experience as ASCO’s First Diversity and Inclusion Officer
Sybil R. Green, JD, RPh, MHA, has been named Diversity and Inclusion Officer by ASCO. A health-care policy expert with experience in both corporate and nonprofit organizations, Ms. Green will guide ASCO’s internal and external initiatives aimed at achieving the Society’s equity, diversity, and...
Leading Health and Cancer Advocacy Groups Unite to Reduce Racial Disparities in Cancer Care
The National Comprehensive Cancer Network (NCCN), American Cancer Society Cancer Action Network (ACS CAN), and National Minority Quality Forum (NMQF) recently presented new ideas for overcoming inequality in oncology. The recommendations—developed by a group of 17 national experts, representing...
ASCO Publishes Guideline Endorsement of ASTRO Guideline for Radiation Therapy in SCLC
An ASCO Expert Panel has endorsed an American Society for Radiation Oncology (ASTRO) guideline on radiation therapy for small cell lung cancer (SCLC), stating the recommendations in the ASTRO guideline “are clear, thorough, and based upon the most relevant scientific evidence” available.1...
Cancer Control in Egypt: Investing in Health
Egypt is a country of 1,010,408 km2 located on the northeast corner of Africa with a population exceeding 100 million. In 2018, there were about 134,632 new cancer cases and 89,042 cancer-related deaths in Egypt. Liver and breast cancers are the most common tumors in terms of incidence and...
Challenges in Managing Hodgkin Lymphoma: Focus on Use of Brentuximab Vedotin
“I was taught that the way of progress was neither swift nor easy.” —Marie Curie To complement The ASCO Post’s continued comprehensive coverage of the 2020 American Society of Hematology (ASH) Annual Meeting & Exposition, here are two abstracts selected from the meeting proceedings focusing on...
Female Breast Cancer Surpasses Lung Cancer as the Most Commonly Diagnosed Cancer Worldwide
Cancer ranks as a leading cause of death in every country in the world, and, for the first time, female breast cancer is the most commonly diagnosed cancer, overtaking lung cancer, according to a collaborative report from the American Cancer Society (ACS) and the International Agency for Research...
American Cancer Society Announces New Diversity in Cancer Research Program
The American Cancer Society recently launched the Diversity in Cancer Research program, a permanent umbrella that will support the American Cancer Society’s effort to foster a more diverse scientific workforce community. This has been made possible through an endowment contribution from Elizabeth...
Lydia Pace, MD, MPH: A Primary Care Physician on the Front Lines of Oncology, Both Nationally and Globally
Lydia Pace, MD, MPH, was inspired to a become a doctor by her grandfather, a general surgeon in New York City, who spoke effulgently of his career in medicine, and by her mother, a social worker who was equally passionate about her profession. A primary care physician, Dr. Pace developed an...
Prevent Cancer Foundation Awards Nine New Research Grants
The Prevent Cancer Foundation has announced funding for nine scientists who are researching cancer prevention and early detection. Each scientist is being awarded $100,000 for 2 years. Areas of focus include the pancreas, esophagus, liver, lungs, skin, prostate, colon-rectum, and blood/bone ...
SGO and FWC Issue Joint Statement on the Elimination of HPV
United in their commitment to eliminate human papillomavirus (HPV)-related cancer, the Society of Gynecologic Oncology (SGO) and the Foundation for Women’s Cancer (FWC) recently endorsed a series of vaccine recommendations. HPV vaccines are among the most effective vaccines available worldwide,...
Sara Schottenstein Foundation, Dedicated to Gastric Cancer, Announces Launch
A science-focused organization dedicated to ending gastric cancer, the Sara Schottenstein Foundation recently announced its launch and its new website, http://www.saraschottensteinfoundation.org. Founded by Jeff Schottenstein, MBA, a wealth management professional in San Francisco, the Sara...
Sachin Apte, MD, MS, MBA, Joins Huntsman Cancer Institute as Chief Clinical Officer
Huntsman Cancer Institute (HCI) and University of Utah (U of U) Health announced the appointment of Sachin Apte, MD, MS, MBA, as Chief Clinical Officer of HCI and Physician-in-Chief of the cancer hospital. “Dr. Apte will lead HCI’s clinical efforts at a time when we are poised to dramatically...
Expert Point of View: Ignatius Ou, MD, PhD
Ignatius Ou, MD, PhD, Health Science Clinical Professor at the University of California Irvine, was invited to discuss the new data from the phase I trials evaluating the antibody drug conjugates patritumab deruxtecan (HER3-DXd)1 and datopotamab deruxtecan (Dato-DXd).2 He noted that TROP2...
Next Up in NSCLC: Antibody-Drug Conjugates
Antibody-drug conjugates directed against HER2, HER3, and trophoblast cell-surface antigen 2 (TROP2) are showing encouraging antitumor activity in advanced non–small cell lung cancer (NSCLC), according to research presented during the virtual edition of the International Association for the Study...
Gynecologic Oncology Leader Named at New Jersey’s Only NCI-Designated Comprehensive Cancer Center
Rutgers Cancer Institute of New Jersey and Robert Wood Johnson University Hospital (RWJUH) have named James K. Aikins, Jr, MD, FACOG, FACS, Chief of Gynecologic Oncology at Rutgers Cancer Institute and Chief of Gynecologic Oncology Services at RWJUH. He will also serve as Program Director for the...
Patrick Delaney Named New Executive Director of NCCN Foundation
The National Comprehensive Cancer Network (NCCN) has announced the appointment of Patrick Delaney as incoming Executive Director for the NCCN Foundation. Mr. Delaney has previously held leadership roles with the Juvenile Diabetes Research Foundation, American Red Cross, and American Cancer Society. ...
Nivolumab Plus Cabozantinib as First-Line Treatment of Advanced Renal Cell Carcinoma
On January 22, 2021, the U.S. Food and Drug Administration approved the combination of nivolumab and cabozantinib as first-line treatment for patients with advanced renal cell carcinoma.1-3 Supporting Efficacy Data Approval was based on the findings of the phase III, open-label CheckMate 9ER trial...
Groundbreaking Cancer Researcher Brian J. Druker, MD, Shows No Signs of Slowing Down
For this installment of the Living a Full Life series, guest editor Jame Abraham, MD, spoke with physician-scientist Brian J. Druker, MD, Director of the Knight Cancer Institute at Oregon Health & Science University, Portland. In 2009, Dr. Druker won the Lasker-DeBakey Clinical Medical Research ...
Expert Point of View: Ana Maria Lopez, MD
Session moderator Ana Maria Lopez, MD, Professor and Vice Chair of Medical Oncology, Sidney Kimmel Medical College, Thomas Jefferson University, and Chief of Cancer Services for the Sidney Kimmel Cancer Center, JeffersonHealth New Jersey, commented on the FluFIT presentation. “This presentation...
